Capricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of some unusual options trading on Thursday. Stock traders acquired 11,316 call options on the stock. This represents an increase of approximately 214% compared to the typical volume of 3,599 call options.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CAPR. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Thursday. HC Wainwright reissued a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $34.50.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP bought a new position in Capricor Therapeutics in the fourth quarter worth approximately $565,000. California State Teachers Retirement System grew its position in shares of Capricor Therapeutics by 1,653.0% during the 4th quarter. California State Teachers Retirement System now owns 32,237 shares of the biotechnology company's stock worth $445,000 after buying an additional 30,398 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Capricor Therapeutics during the fourth quarter valued at $462,000. Voloridge Investment Management LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $1,678,000. Finally, Woodline Partners LP purchased a new stake in Capricor Therapeutics in the fourth quarter worth about $8,693,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Capricor Therapeutics Stock Down 1.3 %

CAPR traded down $0.17 during trading hours on Monday, reaching $12.69. 398,767 shares of the company's stock traded hands, compared to its average volume of 1,384,859. The firm has a 50-day moving average price of $14.06 and a 200 day moving average price of $14.70. The firm has a market capitalization of $577.01 million, a PE ratio of -11.96 and a beta of 4.10. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $11.13 million for the quarter, compared to analysts' expectations of $9.87 million. Equities analysts predict that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.